دورية أكاديمية
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
| العنوان: | Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. |
|---|---|
| المؤلفون: | Shraibman B; From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel., Barnea E; From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel., Kadosh DM; From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel., Haimovich Y; From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel., Slobodin G; §Rheumatology Unit Bnai Zion Medical Center, Haifa 31048, Israel., Rosner I; §Rheumatology Unit Bnai Zion Medical Center, Haifa 31048, Israel., López-Larrea C; ¶Hospital Universitario Central de Asturias, 33011 Oviedo, Asturias, Spain., Hilf N; ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany., Kuttruff S; ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany., Song C; ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany., Britten C; *BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany.; ¶¶¶Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany., Castle J; *BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany., Kreiter S; *BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany., Frenzel K; *BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany., Tatagiba M; ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany., Tabatabai G; ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany., Dietrich PY; §§Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland., Dutoit V; §§Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland., Wick W; ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany., Platten M; ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany., Winkler F; ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany., von Deimling A; ¶¶Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany., Kroep J; ‖‖Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Sahuquillo J; **Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain., Martinez-Ricarte F; **Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain., Rodon J; **Vall d'Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain., Lassen U; ‡‡‡Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark., Ottensmeier C; §§§Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton, UK., van der Burg SH; ‖‖Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.; ¶¶¶Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany., Thor Straten P; ‡‡‡Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark., Poulsen HS; ‖‖‖Rigshospitalet, Departments of Radiation Biology and Oncology, Rigshospitalet 9, Blegdamsvej, DK-2100, Copenhagen, Denmark., Ponsati B; ***BCN Peptides, Pol. Ind. Els Vinyets-Els Fogars II. 08777 Sant Quinti de Mediona (Barcelona), Spain., Okada H; ‡‡‡‡University of California, San Francisco, CA 94131 USA., Rammensee HG; ‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany., Sahin U; *BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany., Singh H; ‖Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany., Admon A; From the ‡Biology, Technion - Israel Institute of Technology, Haifa 32000, Israel; admon@technion.ac.il. |
| المصدر: | Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2018 Nov; Vol. 17 (11), pp. 2132-2145. Date of Electronic Publication: 2018 Aug 02. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 101125647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-9484 (Electronic) Linking ISSN: 15359476 NLM ISO Abbreviation: Mol Cell Proteomics Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [New York, NY] : Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Original Publication: Bethesda, MD : American Society for Biochemistry and Molecular Biology, [2002- |
| مواضيع طبية MeSH: | Antigens, Neoplasm/*blood , Glioblastoma/*blood , HLA Antigens/*metabolism , Peptides/*metabolism , Proteome/*metabolism, Alleles ; Amino Acid Sequence ; Antigens, Neoplasm/metabolism ; Biomarkers, Tumor/blood ; Cell Membrane/metabolism ; Glioblastoma/surgery ; Humans ; Peptides/blood ; Peptides/chemistry ; Solubility |
| مستخلص: | Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Furthermore, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM. (© 2018 Shraibman et al.) |
| التعليقات: | Retracted and Republished in:Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. (PMID: 31154438) Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270. (PMID: 31154440) Erratum in: Mol Cell Proteomics. 2019 Jun;18(6):1270. (PMID: 33500100) |
| References: | Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605) Nucleic Acids Res. 2016 Jan 4;44(D1):D313-6. (PMID: 26578587) Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96. (PMID: 25053711) BMC Immunol. 2008 Jan 22;9:1. (PMID: 18211710) Elife. 2015 Jul 08;4:null. (PMID: 26154972) Cell. 2016 Mar 10;164(6):1233-1247. (PMID: 26967289) Nature. 2017 Jul 13;547(7662):217-221. (PMID: 28678778) J Neurooncol. 2015 Jul;123(3):323-30. (PMID: 26070552) Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18769-76. (PMID: 20974924) Proteomics. 2017 Jan;17(1-2):. (PMID: 27862975) Brain. 2012 Apr;135(Pt 4):1042-54. (PMID: 22418738) Ther Adv Vaccines. 2014 May;2(3):77-89. (PMID: 24790732) Front Oncol. 2015 Jan 29;5:12. (PMID: 25688335) Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900) Science. 1970 Nov 6;170(3958):636-7. (PMID: 5470720) Proteomics. 2016 May;16(10):1570-80. (PMID: 26992070) J Proteome Res. 2006 Apr;5(4):988-94. (PMID: 16602707) Mol Cell Proteomics. 2005 Dec;4(12):1920-32. (PMID: 16127175) Proteomics. 2018 Jun;18(12):e1700284. (PMID: 29505699) Expert Rev Vaccines. 2013 Oct;12(10):1211-7. (PMID: 24090147) Nat Commun. 2016 Nov 21;7:13404. (PMID: 27869121) Immunol Today. 1995 Mar;16(3):124-7. (PMID: 7718084) Curr Opin Immunol. 2015 Jun;34:1-8. (PMID: 25466393) J Clin Invest. 2002 Dec;110(12):1813-22. (PMID: 12488431) Expert Rev Mol Med. 2011 May 13;13:e17. (PMID: 21676290) Proteomics. 2011 Jun;11(12):2528-41. (PMID: 21595034) J Clin Invest. 2016 Dec 1;126(12):4690-4701. (PMID: 27841757) J Neurooncol. 2015 Jul;123(3):433-40. (PMID: 25491947) EMBO J. 2013 Jan 23;32(2):194-203. (PMID: 23258224) Genome Biol. 2009;10(11):R130. (PMID: 19919682) Pharmacol Ther. 2015 Aug;152:63-82. (PMID: 25944528) Tissue Antigens. 2008 Oct;72(4):321-34. (PMID: 18700879) Annu Rev Pharmacol Toxicol. 2014;54:251-72. (PMID: 24160706) Cancer Treat Rev. 2017 Feb;53:79-97. (PMID: 28088073) Biomed Res Int. 2014;2014:437987. (PMID: 25045677) Mol Cell Proteomics. 2015 May;14(5):1361-72. (PMID: 25755296) Ann Transl Med. 2016 Jul;4(14):273. (PMID: 27563660) Mol Cell Proteomics. 2011 Oct;10(10):O111.011833. (PMID: 21813418) Nat Med. 1998 Mar;4(3):321-7. (PMID: 9500606) Mol Cell Proteomics. 2017 Apr;16(4):642-662. (PMID: 28188227) J Neurooncol. 2013 Feb;111(3):285-94. (PMID: 23263746) Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8. (PMID: 9050879) Leuk Res. 2007 Feb;31(2):121-5. (PMID: 16860865) Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. (PMID: 27411023) Proteomics. 2011 Jun;11(11):2336-40. (PMID: 21598389) Proteomics. 2017 Oct;17(19):. (PMID: 28834231) Anticancer Res. 2017 Jan;37(1):21-33. (PMID: 28011470) J Proteome Res. 2011 Apr 1;10(4):1794-805. (PMID: 21254760) Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910) Nature. 2017 Mar 30;543(7647):723-727. (PMID: 28329770) Science. 1992 Mar 6;255(5049):1261-3. (PMID: 1546328) Int J Cancer. 2001 Oct 15;94(2):243-51. (PMID: 11668505) Mol Cell Proteomics. 2016 Jun;15(6):1867-76. (PMID: 26929215) J Chromatogr A. 2002 Dec 6;979(1-2):233-9. (PMID: 12498253) Int J Cancer. 1999 Jan 18;80(2):219-30. (PMID: 9935203) Neurotherapeutics. 2017 Apr;14(2):345-357. (PMID: 28389997) Cancer Res. 2002 Oct 15;62(20):5818-27. (PMID: 12384544) Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. (PMID: 29093164) Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. (PMID: 25548167) Oncotarget. 2016 Feb 2;7(5):5110-7. (PMID: 26819371) J Clin Oncol. 2011 Jan 20;29(3):337-44. (PMID: 21149665) Oncoimmunology. 2015 Jan 9;4(4):e974411. (PMID: 26137405) J Immunol. 2013 Dec 15;191(12):5831-9. (PMID: 24190657) Mol Cell Proteomics. 2015 Mar;14(3):658-73. (PMID: 25576301) Nature. 2008 Apr 3;452(7187):548-52. (PMID: 18385728) Mol Immunol. 2015 Dec;68(2 Pt A):77-80. (PMID: 26118903) Proteomics. 2017 Jan;17(1-2):. (PMID: 27928884) Transplantation. 1996 Mar 27;61(6):984-7. (PMID: 8623175) Can J Neurol Sci. 2016 Jul;43(4):494-502. (PMID: 27324313) Blood. 2015 Sep 3;126(10):1203-13. (PMID: 26138685) Mol Cell Proteomics. 2013 Jul;12(7):1853-64. (PMID: 23538226) Curr Neurol Neurosci Rep. 2015 Jan;15(1):508. (PMID: 25431096) Mol Cell Proteomics. 2015 Dec;14(12):3105-17. (PMID: 26628741) Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375) Nature. 1970 Apr 25;226(5243):366-7. (PMID: 5309633) BMC Genomics. 2014 Jan 24;15:63. (PMID: 24460756) Oncoimmunology. 2016 Jun 30;5(8):e1204504. (PMID: 27622074) Neurosurg Rev. 1994;17(3):211-5. (PMID: 7838400) Autoimmun Rev. 2012 Jul;11(9):627-35. (PMID: 22100331) Nucleic Acids Res. 2009 Jan;37(Database issue):D816-9. (PMID: 18838390) Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1591-9. (PMID: 24715725) Mol Cell Proteomics. 2016 Sep;15(9):3058-70. (PMID: 27412690) Curr Opin Immunol. 2016 Aug;41:9-17. (PMID: 27155075) |
| معلومات مُعتمدة: | 15951 United Kingdom CRUK_ Cancer Research UK; MR/P024351/1 United Kingdom MRC_ Medical Research Council |
| فهرسة مساهمة: | Keywords: CTA - cancer/testis antigens; Cancer biomarker(s); Cancer therapeutics; Glioblastoma; HLA - human leukocytes antigen; Immunoaffinity; Immunology; MHC - major histocompatibility complex; Peptidomics; Plasma or serum analysis; immunotherapy |
| المشرفين على المادة: | 0 (Antigens, Neoplasm) 0 (Biomarkers, Tumor) 0 (HLA Antigens) 0 (Peptides) 0 (Proteome) |
| تواريخ الأحداث: | Date Created: 20180804 Date Completed: 20190517 Latest Revision: 20240229 |
| رمز التحديث: | 20240229 |
| مُعرف محوري في PubMed: | PMC6210219 |
| DOI: | 10.1074/mcp.RA118.000792 |
| PMID: | 30072578 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-9484 |
|---|---|
| DOI: | 10.1074/mcp.RA118.000792 |